Intelligent Bio Solutions Inc. announced its financial results for the fiscal fourth quarter and full-year ended June 30, 2025, showcasing growth driven by higher-margin cartridge sales and operational streamlining.
The company advanced efforts to secure U.S. FDA 510(k) clearance to expand into the U.S. market beyond current Forensic Use Only settings.
Quarterly and year-on-year revenue growth of 16% was supported by increased demand for drug testing cartridges.
FDA Clearance Progress
INBS focused on securing FDA 510(k) clearance for its opiate test system, advancing regulatory strategies and generating new clinical data.
Revenue Growth
Revenue from sales of goods in fiscal Q4 increased by 16% year-on-year, with cartridge sales contributing significantly to the growth.
Market Expansion
The company secured 115 new accounts during the year, with distributor partnerships driving growth in transport, logistics, and construction sectors.
- INBS continues to expand its commercial presence internationally, with over 450 active customer accounts across 24 countries and 18 distribution partners.
- Revenue from cartridge sales saw steady growth, contributing to a higher-margin revenue stream and reinforcing the recurring revenue model.
The fiscal year 2025 marked a significant period of growth and strategic development for Intelligent Bio Solutions Inc., setting the stage for further expansion into the U.S. market and continued revenue growth. The company's focus on operational efficiency and market localization is expected to drive future success.